{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:05Z","timestamp":1792783385230,"version":"4.5.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Department of Health Research, India","award":["R.11013\/27\/2021-GIA\/HR"],"award-info":[{"award-number":["R.11013\/27\/2021-GIA\/HR"]}],"id":[{"id":"https:\/\/ror.org\/00z72fs19","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Indian Council of Medical Research","award":["No. 90\/24\/2012\/SCRT\/BMS"],"award-info":[{"award-number":["No. 90\/24\/2012\/SCRT\/BMS"]}],"id":[{"id":"https:\/\/ror.org\/0492wrx28","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03443-y","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:16:39Z","timestamp":1792469799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The interplay of integrin, VE-cadherin, and \u03b2-catenin signaling triad in angiogenesis: regulation by Wnt antagonist, secreted frizzled related protein 4 in the tumor angiogenic loop"],"prefix":"10.1007","volume":"43","author":[{"given":"Aishwarya","family":"Janaki P","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naisarg","family":"Gamit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preet","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Dharmarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Warrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"3443_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/s12967-023-04286-1","volume":"21","author":"Z Luo","year":"2023","unstructured":"Luo Z, Yao J, Wang Z, Xu J. Mitochondria in endothelial cells angiogenesis and function: current understanding and future perspectives. J Transl Med. 2023;21:441. https:\/\/doi.org\/10.1186\/s12967-023-04286-1 1IF: 9.7 Q1 B2.","journal-title":"J Transl Med"},{"key":"3443_CR2","doi-asserted-by":"publisher","unstructured":"Zhu H, Zhao W, Chen H, et al. Evaluation of the effectiveness and safety of combining PD-1\/PD-L1 inhibitors with anti-angiogenic agents in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1468440 IF: 7.0 Q1 B2.","DOI":"10.3389\/fimmu.2024.1468440"},{"key":"3443_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10456-023-09876-7","volume":"26","author":"AC Dudley","year":"2023","unstructured":"Dudley AC, Griffioen AW. Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis. 2023;26:313\u201347. https:\/\/doi.org\/10.1007\/s10456-023-09876-7 IF: 11.2 Q1 B1.","journal-title":"Angiogenesis"},{"key":"3443_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"Z-L Liu","year":"2023","unstructured":"Liu Z-L, Chen H-H, Zheng L-L, et al. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8:198. https:\/\/doi.org\/10.1038\/s41392-023-01460-1 IF: 81.2 Q1 B1.","journal-title":"Signal Transduct Target Ther"},{"key":"3443_CR5","doi-asserted-by":"publisher","unstructured":"Bu LL, Yuan HH, Xie LL, et al. New dawn for atherosclerosis: vascular endothelial cell senescence and death. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms242015160 IF: 5.6 Q1 B3.","DOI":"10.3390\/ijms242015160"},{"key":"3443_CR6","doi-asserted-by":"publisher","first-page":"e0310557","DOI":"10.1371\/journal.pone.0310557","volume":"19","author":"NM Ayoub","year":"2024","unstructured":"Ayoub NM, Sardiah S, Al-Share QY, Alkader MS. Exploring angiogenic pathways in breast cancer: Clinicopathologic correlations and prognostic implications based on gene expression profiles from a large-scale genomic dataset. PLoS ONE. 2024;19:e0310557. https:\/\/doi.org\/10.1371\/journal.pone.0310557 IF: 2.8 Q2 B3.","journal-title":"PLoS ONE"},{"key":"3443_CR7","doi-asserted-by":"publisher","first-page":"102240","DOI":"10.1016\/j.tice.2023.102240","volume":"85","author":"P Mankuzhy","year":"2023","unstructured":"Mankuzhy P, Dharmarajan A, Perumalsamy LR, et al. The role of Wnt signaling in mesenchymal stromal cell-driven angiogenesis. Tissue Cell. 2023;85:102240. https:\/\/doi.org\/10.1016\/j.tice.2023.102240 IF: 3.1 Q1 B3.","journal-title":"Tissue Cell"},{"key":"3443_CR8","first-page":"131","volume":"38","author":"JJ Olsen","year":"2017","unstructured":"Olsen JJ, Pohl S, \u00f6ther G, Deshmukh A, et al. The role of Wnt signalling in angiogenesis. Clin Biochemist Reviews. 2017;38:131\u201342.","journal-title":"Clin Biochemist Reviews"},{"key":"3443_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-025-02142-w","volume":"10","author":"C Xue","year":"2025","unstructured":"Xue C, Chu Q, Shi Q, et al. Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances. Signal Transduct Target Ther. 2025;10:106. https:\/\/doi.org\/10.1038\/s41392-025-02142-w IF: 81.2 Q1 B1.","journal-title":"Signal Transduct Target Ther"},{"key":"3443_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.gendis.2023.01.030","volume":"11","author":"K Qin","year":"2024","unstructured":"Qin K, Yu M, Fan J, et al. Canonical and noncanonical Wnt signaling: Multilayered mediators, signaling mechanisms and major signaling crosstalk. Genes Dis. 2024;11:103\u201334. https:\/\/doi.org\/10.1016\/j.gendis.2023.01.030 IF: 14.6 Q1 B2 1 comment on PubPeer (by: Gerris Caucasicus).","journal-title":"Genes Dis"},{"key":"3443_CR11","doi-asserted-by":"publisher","unstructured":"Kacker S, Parsad V, Singh N, et al. Planar Cell Polarity Signaling: Coordinated Crosstalk for Cell Orientation. J Dev Biol. 2024;12. https:\/\/doi.org\/10.3390\/jdb12020012 IF: 2.4 Q2 B4.","DOI":"10.3390\/jdb12020012"},{"key":"3443_CR12","doi-asserted-by":"publisher","unstructured":"Nair NY, Samuel V, Ramesh L, et al. Actin cytoskeleton in angiogenesis. Biol Open. 2022;11. https:\/\/doi.org\/10.1242\/bio.058899 IF: 1.8 Q3 B4.","DOI":"10.1242\/bio.058899"},{"key":"3443_CR13","doi-asserted-by":"publisher","unstructured":"Peri SS, Narayanaa YK, Hubert TD, et al. Navigating Tumour Microenvironment and Wnt Signalling Crosstalk: Implications for Advanced Cancer Therapeutics. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15245847 IF: 4.8 Q2 B3.","DOI":"10.3390\/cancers15245847"},{"key":"3443_CR14","doi-asserted-by":"publisher","unstructured":"Zhu Y, Li X. Advances of Wnt signalling pathway in colorectal cancer. Cells. 2023;12. https:\/\/doi.org\/10.3390\/cells12030447 IF: 6.0 Q2 B2.","DOI":"10.3390\/cells12030447"},{"key":"3443_CR15","doi-asserted-by":"publisher","first-page":"e0284131","DOI":"10.1371\/journal.pone.0284131","volume":"18","author":"M Yamakuchi","year":"2023","unstructured":"Yamakuchi M, Okawa M, Takenouchi K, et al. VEGF-A165 is the predominant VEGF-A isoform in platelets, while VEGF-A121 is abundant in serum and plasma from healthy individuals. PLoS ONE. 2023;18:e0284131. https:\/\/doi.org\/10.1371\/journal.pone.0284131 IF: 2.8 Q2 B3.","journal-title":"PLoS ONE"},{"key":"3443_CR16","doi-asserted-by":"publisher","first-page":"33384","DOI":"10.1039\/d4ra05244g","volume":"14","author":"PJ Chaudhari","year":"2024","unstructured":"Chaudhari PJ, Nemade AR, Shirkhedkar AA. Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents. RSC Adv. 2024;14:33384\u2013417. https:\/\/doi.org\/10.1039\/d4ra05244g IF: 6.1 Q2 B3.","journal-title":"RSC Adv"},{"key":"3443_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.25122\/jml-2022-0283","volume":"16","author":"RF Savka","year":"2023","unstructured":"Savka RF, Mykolaiovych Berbets A, Mykhailovych Barbe A, et al. Changes in concentrations of melatonin, PlGF, and cytokines in women with preeclampsia. J Med Life. 2023;16:471\u20136. https:\/\/doi.org\/10.25122\/jml-2022-0283 IF: NA NA NA.","journal-title":"J Med Life"},{"key":"3443_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-022-01310-7","volume":"15","author":"Y Liu","year":"2022","unstructured":"Liu Y, Li Y, Wang Y, et al. Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. J Hematol Oncol. 2022;15:1\u201328. https:\/\/doi.org\/10.1186\/s13045-022-01310-7 IF: 47.8 Q1 B1.","journal-title":"J Hematol Oncol"},{"key":"3443_CR19","doi-asserted-by":"publisher","first-page":"100009","DOI":"10.1016\/j.medidd.2019.100009","volume":"2","author":"SJ Modi","year":"2019","unstructured":"Modi SJ, Kulkarni VM. Vascular endothelial growth factor receptor (vegfr-2)\/kdr inhibitors: medicinal chemistry perspective. Med Drug Discov. 2019;2:100009. https:\/\/doi.org\/10.1016\/j.medidd.2019.100009 IF: NA NA NA.","journal-title":"Med Drug Discov"},{"key":"3443_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","volume":"23","author":"DJ Hicklin","year":"2005","unstructured":"Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011\u201327. https:\/\/doi.org\/10.1200\/JCO.2005.06.081 IF: 44.7 Q1 B1.","journal-title":"J Clin Oncol"},{"key":"3443_CR21","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1038\/sj.onc.1201380","volume":"15","author":"S Rousseau","year":"1997","unstructured":"Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene. 1997;15:2169\u201377. https:\/\/doi.org\/10.1038\/sj.onc.1201380 IF: 9.1 Q1 B1.","journal-title":"Oncogene"},{"key":"3443_CR22","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1097\/01243894-200610000-00003","volume":"1","author":"M Nilsson","year":"2006","unstructured":"Nilsson M, Heymach JV. Vascular endothelial growth factor (VEGF) pathway. J Thorac Oncol. 2006;1:768\u201370.","journal-title":"J Thorac Oncol"},{"key":"3443_CR23","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/sj.bjc.6604921","volume":"100","author":"XB Trinh","year":"2009","unstructured":"Trinh XB, Tjalma WAA, Vermeulen PB, et al. The VEGF pathway and the AKT\/mTOR\/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer. 2009;100:971\u20138. https:\/\/doi.org\/10.1038\/sj.bjc.6604921 IF: 7.8 Q1 B2.","journal-title":"Br J Cancer"},{"key":"3443_CR24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.bcmd.2007.04.001","volume":"39","author":"ZK Otrock","year":"2007","unstructured":"Otrock ZK, Mahfouz RAR, Makarem JA, Shamseddine AI. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis. 2007;39:212\u201320. https:\/\/doi.org\/10.1016\/j.bcmd.2007.04.001 IF: 2.1 Q3 B4.","journal-title":"Blood Cells Mol Dis"},{"key":"3443_CR25","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","volume":"77","author":"R Lugano","year":"2020","unstructured":"Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77:1745\u201370. https:\/\/doi.org\/10.1007\/s00018-019-03351-7 IF: 6.5 Q1 B2.","journal-title":"Cell Mol Life Sci"},{"key":"3443_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/15216540252774784","volume":"52","author":"S Kliche","year":"2001","unstructured":"Kliche S, Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life. 2001;52:61\u20136. https:\/\/doi.org\/10.1080\/15216540252774784 IF: 3.2 Q3 B3.","journal-title":"IUBMB Life"},{"key":"3443_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphys.2020.623769","volume":"11","author":"AC Vion","year":"2021","unstructured":"Vion AC, Perovic T, Petit C, et al. Endothelial Cell Orientation and Polarity Are Controlled by Shear Stress and VEGF Through Distinct Signaling Pathways. Front Physiol. 2021;11:1\u201316. https:\/\/doi.org\/10.3389\/fphys.2020.623769 IF: 4.3 Q1 B3.","journal-title":"Front Physiol"},{"key":"3443_CR28","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/nm1095-1024","volume":"1","author":"T Alon","year":"1995","unstructured":"Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1:1024\u20138. https:\/\/doi.org\/10.1038\/nm1095-1024 IF: 52.5 Q1 B1.","journal-title":"Nat Med"},{"key":"3443_CR29","doi-asserted-by":"publisher","first-page":"13313","DOI":"10.1074\/jbc.273.21.13313","volume":"273","author":"HP Gerber","year":"1998","unstructured":"Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem. 1998;273:13313\u20136. https:\/\/doi.org\/10.1074\/jbc.273.21.13313 IF: 4.1 Q2 B2.","journal-title":"J Biol Chem"},{"key":"3443_CR30","doi-asserted-by":"publisher","first-page":"175586","DOI":"10.1016\/j.ejphar.2023.175586","volume":"949","author":"S Ghalehbandi","year":"2023","unstructured":"Ghalehbandi S, Yuzugulen J, Pranjol MZI, Pourgholami MH. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur J Pharmacol. 2023;949:175586. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175586 IF: 5.7 Q1 B3.","journal-title":"Eur J Pharmacol"},{"key":"3443_CR31","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s00432-020-03225-7","volume":"146","author":"K Abbink","year":"2020","unstructured":"Abbink K, Zusterzeel PLM, Geurts-Moespot A, et al. Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer. J Cancer Res Clin Oncol. 2020;146:1725\u201335. https:\/\/doi.org\/10.1007\/s00432-020-03225-7 IF: 3.3 Q2 B4.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3443_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.62347\/CXDC6773","volume":"18","author":"K Xu","year":"2025","unstructured":"Xu K, Lou C. Effects of serum HIF-1\u03b1, VEGF, and uPA levels on clinicopathologic findings and prognosis in oral squamous cell carcinoma. Int J Clin Exp Pathol. 2025;18:12\u201322. https:\/\/doi.org\/10.62347\/CXDC6773 IF: 1.3 Q3 B4.","journal-title":"Int J Clin Exp Pathol"},{"key":"3443_CR33","first-page":"455","volume":"59","author":"CS Melincovici","year":"2018","unstructured":"Melincovici CS, Bo\u015fca AB, \u015eu\u015fman S, et al. Vascular endothelial growth factor (VEGF) \u2013 key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59:455\u201367.","journal-title":"Rom J Morphol Embryol"},{"key":"3443_CR34","doi-asserted-by":"publisher","unstructured":"Zheng Y, Wang J, Zhao T, et al. Modulation of the VEGF\/AKT\/eNOS signaling pathway to regulate liver angiogenesis to explore the anti-hepatic fibrosis mechanism of curcumol. J Ethnopharmacol. 2021;280. https:\/\/doi.org\/10.1016\/j.jep.2021.114480 IF: 6.8 Q1 B2.","DOI":"10.1016\/j.jep.2021.114480"},{"key":"3443_CR35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s12079-016-0352-8","volume":"10","author":"CS Abhinand","year":"2016","unstructured":"Abhinand CS, Raju R, Soumya SJ, et al. VEGF-A\/VEGFR2 signaling network in endothelial cells relevant to angiogenesis. J Cell Commun Signal. 2016;10:347\u201354. https:\/\/doi.org\/10.1007\/s12079-016-0352-8 IF: 4.0 Q3 B3.","journal-title":"J Cell Commun Signal"},{"key":"3443_CR36","doi-asserted-by":"publisher","unstructured":"Delgado-Bellido D, Oliver FJ, Vargas Padilla MV, et al. VE-Cadherin in Cancer-Associated Angiogenesis: A Deceptive Strategy of Blood Vessel Formation. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms24119343 .","DOI":"10.3390\/ijms24119343"},{"key":"3443_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/s0092-8674(00)81010-7","volume":"98","author":"P Carmeliet","year":"1999","unstructured":"Carmeliet P, Lampugnani MG, Moons L, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell. 1999;98:147\u201357. https:\/\/doi.org\/10.1016\/s0092-8674(00)81010-7 IF: 45.1 Q1 B1.","journal-title":"Cell"},{"key":"3443_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4161\/cam.28243","volume":"8","author":"A Abu Taha","year":"2014","unstructured":"Abu Taha A, Schnittler H-J. Dynamics between actin and the VE-cadherin\/catenin complex: novel aspects of the ARP2\/3 complex in regulation of endothelial junctions. Cell Adh Migr. 2014;8:125\u201335. https:\/\/doi.org\/10.4161\/cam.28243 IF: 4.3 Q2 B3.","journal-title":"Cell Adh Migr"},{"key":"3443_CR39","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1083\/jcb.127.6.2061","volume":"127","author":"J H\u00fclsken","year":"1994","unstructured":"H\u00fclsken J, Birchmeier W, Behrens J. E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J Cell Biol. 1994;127:2061\u20139. https:\/\/doi.org\/10.1083\/jcb.127.6.2061 IF: 6.1 Q2 B1.","journal-title":"J Cell Biol"},{"key":"3443_CR40","doi-asserted-by":"publisher","first-page":"1234104","DOI":"10.3389\/fphys.2023.1234104","volume":"14","author":"W Nan","year":"2023","unstructured":"Nan W, He Y, Wang S, Zhang Y. Molecular mechanism of VE-cadherin in regulating endothelial cell behaviour during angiogenesis. Front Physiol. 2023;14:1234104. https:\/\/doi.org\/10.3389\/fphys.2023.1234104 IF: 4.3 Q1 B3.","journal-title":"Front Physiol"},{"key":"3443_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1091\/mbc.E16-08-0616","volume":"28","author":"JP Garrett","year":"2017","unstructured":"Garrett JP, Lowery AM, Adam AP, et al. Regulation of endothelial barrier function by p120-catenin\u2219VE-cadherin interaction. Mol Biol Cell. 2017;28:85\u201397. https:\/\/doi.org\/10.1091\/mbc.E16-08-0616 IF: 3.0 Q3 B2.","journal-title":"Mol Biol Cell"},{"key":"3443_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-025-93756-1","volume":"15","author":"I Hamad","year":"2025","unstructured":"Hamad I, Sepic S, Moztarzadeh S, et al. Plakoglobin does not participate in endothelial barrier stabilization mediated by cAMP. Sci Rep. 2025;15:1\u201319. https:\/\/doi.org\/10.1038\/s41598-025-93756-1 IF: 4.9 Q1 B3.","journal-title":"Sci Rep"},{"key":"3443_CR43","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1749-6632.2000.tb06320.x","volume":"902","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P, Collen D. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann N Y Acad Sci. 2000;902:249\u201364. https:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb06320.x IF: 4.5 Q1 B2.","journal-title":"Ann N Y Acad Sci"},{"key":"3443_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-023-05666-7","volume":"14","author":"D Delgado-Bellido","year":"2023","unstructured":"Delgado-Bellido D, Zamudio-Mart\u00ednez E, Fern\u00e1ndez-Cort\u00e9s M, et al. VE-Cadherin modulates \u03b2-catenin\/TCF-4 to enhance Vasculogenic Mimicry. Cell Death Dis. 2023;14:1\u201311. https:\/\/doi.org\/10.1038\/s41419-023-05666-7 IF: 12.2 Q1 B1.","journal-title":"Cell Death Dis"},{"key":"3443_CR45","doi-asserted-by":"publisher","first-page":"eabm8965","DOI":"10.1126\/sciadv.abm8965","volume":"8","author":"K Yang","year":"2022","unstructured":"Yang K, Fan M, Wang X, et al. Lactate induces vascular permeability via disruption of VE-cadherin in endothelial cells during sepsis. Sci Adv. 2022;8:eabm8965. https:\/\/doi.org\/10.1126\/sciadv.abm8965 IF: 13.9 Q1 B1.","journal-title":"Sci Adv"},{"key":"3443_CR46","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.20892\/j.issn.2095-3941.2025.0048","volume":"22","author":"S Serrat\u00ec","year":"2025","unstructured":"Serrat\u00ec S, Raho L, De Giosa G, et al. Unraveling vascular mechanisms in melanoma: roles of angiogenesis and vasculogenic mimicry in tumor progression and therapeutic resistance. Cancer Biol Med. 2025;22:1327\u201352. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2025.0048 IF: 12.4 Q1 B2.","journal-title":"Cancer Biol Med"},{"key":"3443_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12943-017-0631-x","volume":"16","author":"D Delgado-Bellido","year":"2017","unstructured":"Delgado-Bellido D, Serrano-Saenz S, Fern\u00e1ndez-Cort\u00e9s M, Oliver FJ. Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin. Mol Cancer. 2017;16:65. https:\/\/doi.org\/10.1186\/s12943-017-0631-x IF: 42.2 Q1 B1.","journal-title":"Mol Cancer"},{"key":"3443_CR48","doi-asserted-by":"publisher","first-page":"106333","DOI":"10.1016\/j.phrs.2022.106333","volume":"182","author":"C Qian","year":"2022","unstructured":"Qian C, Yang C, Tang Y, et al. Pharmacological manipulation of Ezh2 with salvianolic acid B results in tumor vascular normalization and synergizes with cisplatin and T cell-mediated immunotherapy. Pharmacol Res. 2022;182:106333. https:\/\/doi.org\/10.1016\/j.phrs.2022.106333 IF: 12.2 Q1 B2.","journal-title":"Pharmacol Res"},{"key":"3443_CR49","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1038\/s41467-022-30556-5","volume":"13","author":"A Byron","year":"2022","unstructured":"Byron A, Griffith BGC, Herrero A, et al. Characterisation of a nucleo-adhesome. Nat Commun. 2022;13:3053. https:\/\/doi.org\/10.1038\/s41467-022-30556-5 IF: 18.1 Q1 B1.","journal-title":"Nat Commun"},{"key":"3443_CR50","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.omtn.2021.01.001","volume":"23","author":"R Yuan","year":"2021","unstructured":"Yuan R, Li Y, Yang B, et al. LOXL1 exerts oncogenesis and stimulates angiogenesis through the LOXL1-FBLN5\/\u03b1v\u03b23 integrin\/FAK-MAPK axis in ICC. Mol Ther Nucleic Acids. 2021;23:797\u2013810. https:\/\/doi.org\/10.1016\/j.omtn.2021.01.001 IF: 6.5 Q1 B2.","journal-title":"Mol Ther Nucleic Acids"},{"key":"3443_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01259-6","author":"X Pang","year":"2023","unstructured":"Pang X, He X, Qiu Z, et al. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct Target Ther. 2023. https:\/\/doi.org\/10.1038\/s41392-022-01259-6 IF: 81.2 Q1 B1.","journal-title":"Signal Transduct Target Ther"},{"key":"3443_CR52","doi-asserted-by":"publisher","first-page":"106694","DOI":"10.1016\/j.phrs.2023.106694","volume":"189","author":"Y Gu","year":"2023","unstructured":"Gu Y, Dong B, He X, et al. The challenges and opportunities of \u03b1v\u03b23-based therapeutics in cancer: From bench to clinical trials. Pharmacol Res. 2023;189:106694. https:\/\/doi.org\/10.1016\/j.phrs.2023.106694 IF: 12.2 Q1 B2.","journal-title":"Pharmacol Res"},{"key":"3443_CR53","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41390-020-01177-9","volume":"89","author":"OJ Mezu-Ndubuisi","year":"2021","unstructured":"Mezu-Ndubuisi OJ, Maheshwari A. The role of integrins in inflammation and angiogenesis. Pediatr Res. 2021;89:1619\u201326. https:\/\/doi.org\/10.1038\/s41390-020-01177-9 IF: 3.3 Q1 B3.","journal-title":"Pediatr Res"},{"key":"3443_CR54","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.critrevonc.2015.05.018","volume":"96","author":"S Stucci","year":"2015","unstructured":"Stucci S, Tucci M, Passarelli A, Silvestris F. Av\u03b23 integrin: Pathogenetic role in osteotropic tumors. Crit Rev Oncol Hematol. 2015;96:183\u201393. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.05.018 IF: 6.2 Q1 B2.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3443_CR55","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/bjc.2017.214","volume":"117","author":"L Jiang","year":"2017","unstructured":"Jiang L, Luan Y, Miao X, et al. Platelet releasate promotes breast cancer growth and angiogenesis via VEGF-integrin cooperative signalling. Br J Cancer. 2017;117:695\u2013703. https:\/\/doi.org\/10.1038\/bjc.2017.214 IF: 7.8 Q1 B2.","journal-title":"Br J Cancer"},{"key":"3443_CR56","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1046\/j.1523-1747.2001.01352.x","volume":"116","author":"GJ Thomas","year":"2001","unstructured":"Thomas GJ, Poomsawat S, Lewis MP, et al. alpha v beta 6 Integrin upregulates matrix metalloproteinase 9 and promotes migration of normal oral keratinocytes. J Invest Dermatol. 2001;116:898\u2013904. https:\/\/doi.org\/10.1046\/j.1523-1747.2001.01352.x.","journal-title":"J Invest Dermatol"},{"key":"3443_CR57","first-page":"836","volume":"87","author":"R Ria","year":"2002","unstructured":"Ria R, Vacca A, Ribatti D, et al. Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica. 2002;87:836\u201345.","journal-title":"Haematologica"},{"key":"3443_CR58","doi-asserted-by":"publisher","first-page":"9482","DOI":"10.1073\/pnas.1633689100","volume":"100","author":"M Rolli","year":"2003","unstructured":"Rolli M, Fransvea E, Pilch J, et al. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:9482\u20137. https:\/\/doi.org\/10.1073\/pnas.1633689100 IF: 9.5 Q1 B1.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3443_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nano10030581","volume":"10","author":"R Nagaraj","year":"2020","unstructured":"Nagaraj R, Stack T, Yi S, et al. High density display of an anti-angiogenic peptide on micelle surfaces enhances their inhibition of \u03b1v\u03b23 integrin-mediated neovascularization in vitro. Nanomaterials. 2020;10:1\u201318. https:\/\/doi.org\/10.3390\/nano10030581 IF: 4.8 Q2 B3.","journal-title":"Nanomaterials"},{"key":"3443_CR60","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.1128\/MCB.19.8.5576","volume":"19","author":"D Gradl","year":"1999","unstructured":"Gradl D, K\u00fchl M, Wedlich D. The Wnt\/Wg signal transducer beta-catenin controls fibronectin expression. Mol Cell Biol. 1999;19:5576\u201387. https:\/\/doi.org\/10.1128\/MCB.19.8.5576 IF: 2.8 Q3 B3.","journal-title":"Mol Cell Biol"},{"key":"3443_CR61","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/emboj\/18.4.882","volume":"18","author":"R Soldi","year":"1999","unstructured":"Soldi R, Mitola S, Strasly M, et al. Role of \u03b1(v)\u03b23 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 1999;18:882\u201392. https:\/\/doi.org\/10.1093\/emboj\/18.4.882 IF: 8.4 Q1 B1.","journal-title":"EMBO J"},{"key":"3443_CR62","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1379\/1466-1268(2003)8<37:IVRFVA>2.0.CO;2","volume":"8","author":"B Masson-Gadais","year":"2003","unstructured":"Masson-Gadais B, Houle F, Laferri\u00e8re J, Huot J. Integrin \u03b1v\u03b23 requirement for VEGFR2-mediated activation of SAPK2\/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones. 2003;8:37\u201352. https:\/\/doi.org\/10.1379\/1466-1268(2003)8%3C37:IVRFVA%3E2.0.CO;2.","journal-title":"Cell Stress Chaperones"},{"key":"3443_CR63","first-page":"2824","volume":"62","author":"M Trikha","year":"2002","unstructured":"Trikha M, Zhou Z, Timar J, et al. Multiple roles for platelet GPIIb\/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res. 2002;62:2824\u201333.","journal-title":"Cancer Res"},{"key":"3443_CR64","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.matbio.2024.04.003","volume":"130","author":"SM Haake","year":"2024","unstructured":"Haake SM, Rios BL, Pozzi A, Zent R. Integrating integrins with the hallmarks of cancer. Matrix Biol. 2024;130:20\u201335. https:\/\/doi.org\/10.1016\/j.matbio.2024.04.003 IF: 5.9 Q1 B1.","journal-title":"Matrix Biol"},{"key":"3443_CR65","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.7512751","volume":"264","author":"PC Brooks","year":"1994","unstructured":"Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569\u201371.","journal-title":"Science"},{"key":"3443_CR66","first-page":"3145","volume":"63","author":"V Easwaran","year":"2003","unstructured":"Easwaran V, Lee SH, Inge L, et al. beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res. 2003;63:3145\u201353.","journal-title":"Cancer Res"},{"key":"3443_CR67","doi-asserted-by":"publisher","unstructured":"Zhong L, Pan Y, Shen J. FBXW7 inhibits invasion, migration and angiogenesis in ovarian cancer cells by suppressing VEGF expression through inactivation of \u03b2-catenin signaling. Exp Ther Med. 2021;21. https:\/\/doi.org\/10.3892\/etm.2021.9945 IF: 2.2 Q3 B4.","DOI":"10.3892\/etm.2021.9945"},{"key":"3443_CR68","doi-asserted-by":"publisher","first-page":"119234","DOI":"10.1016\/j.lfs.2021.119234","volume":"272","author":"Y Fei","year":"2021","unstructured":"Fei Y, Zhao B, Zhu J, et al. XQ-1H promotes cerebral angiogenesis via activating PI3K\/Akt\/GSK3\u03b2\/\u03b2-catenin\/VEGF signal in mice exposed to cerebral ischemic injury. Life Sci. 2021;272:119234. https:\/\/doi.org\/10.1016\/j.lfs.2021.119234 IF: 6.4 Q1 B3.","journal-title":"Life Sci"},{"key":"3443_CR69","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.7150\/ijms.52206","volume":"18","author":"B Wu","year":"2021","unstructured":"Wu B, Zhu J, Dai X, et al. Raddeanin A inhibited epithelial-mesenchymal transition (EMT) and angiogenesis in glioblastoma by downregulating \u03b2-catenin expression. Int J Med Sci. 2021;18:1609\u201317. https:\/\/doi.org\/10.7150\/ijms.52206 IF: 3.7 Q1 B3.","journal-title":"Int J Med Sci"},{"key":"3443_CR70","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41388-020-01588-2","volume":"40","author":"H Yousefi","year":"2021","unstructured":"Yousefi H, Vatanmakanian M, Mahdiannasser M, et al. Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance. Oncogene. 2021;40:1043\u201363. https:\/\/doi.org\/10.1038\/s41388-020-01588-2 IF: 9.1 Q1 B1.","journal-title":"Oncogene"},{"key":"3443_CR71","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36:1461\u201373. https:\/\/doi.org\/10.1038\/onc.2016.304 IF: 9.1 Q1 B1.","journal-title":"Oncogene"},{"key":"3443_CR72","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1002\/ijc.32359","volume":"145","author":"Z Wang","year":"2019","unstructured":"Wang Z, Li Y, Xiao Y, et al. Integrin \u03b19 depletion promotes \u03b2-catenin degradation to suppress triple-negative breast cancer tumor growth and metastasis. Int J Cancer. 2019;145:2767\u201380. https:\/\/doi.org\/10.1002\/ijc.32359 IF: 4.9 Q2 B2.","journal-title":"Int J Cancer"},{"key":"3443_CR73","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12964-019-0464-x","volume":"17","author":"X-X Zuo","year":"2019","unstructured":"Zuo X-X, Yang Y, Zhang Y, et al. Platelets promote breast cancer cell MCF-7 metastasis by direct interaction: surface integrin \u03b12\u03b21-contacting-mediated activation of Wnt-\u03b2-catenin pathway. Cell Commun Signal. 2019;17:142. https:\/\/doi.org\/10.1186\/s12964-019-0464-x IF: 11.6 Q1 B2.","journal-title":"Cell Commun Signal"},{"key":"3443_CR74","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/15384047.2018.1529101","volume":"20","author":"S Cheng","year":"2019","unstructured":"Cheng S, Huang Y, Lou C, et al. FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin \u03b23\/Wnt signaling under miR-137 regulation. Cancer Biol Ther. 2019;20:328\u201337. https:\/\/doi.org\/10.1080\/15384047.2018.1529101 IF: 5.7 Q1 B2.","journal-title":"Cancer Biol Ther"},{"key":"3443_CR75","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fphar.2015.00279","volume":"6","author":"A-F Blandin","year":"2015","unstructured":"Blandin A-F, Renner G, Lehmann M, et al. \u03b21 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer. Front Pharmacol. 2015;6:279. https:\/\/doi.org\/10.3389\/fphar.2015.00279 IF: 5.4 Q1 B3.","journal-title":"Front Pharmacol"},{"key":"3443_CR76","doi-asserted-by":"publisher","first-page":"40387","DOI":"10.18632\/oncotarget.9617","volume":"7","author":"H Yi","year":"2016","unstructured":"Yi H, Zeng D, Shen Z, et al. Integrin alphavbeta3 enhances \u03b2-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity. Oncotarget. 2016;7:40387\u201397. https:\/\/doi.org\/10.18632\/oncotarget.9617 IF: NA NA NA.","journal-title":"Oncotarget"},{"key":"3443_CR77","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.22038\/IJBMS.2021.58716.13042","volume":"24","author":"SM Sar\u0131 K\u0131l\u0131\u00e7aslan","year":"2021","unstructured":"Sar\u0131 K\u0131l\u0131\u00e7aslan SM, \u0130ncesu Z. Effects of integrin-linked kinase on protein kinase b, glycogen synthase kinase-3\u03b2, and \u03b2-catenin molecules in ovarian cancer cells. Iran J Basic Med Sci. 2021;24:1500\u20138. https:\/\/doi.org\/10.22038\/IJBMS.2021.58716.13042.","journal-title":"Iran J Basic Med Sci"},{"key":"3443_CR78","doi-asserted-by":"publisher","first-page":"751578","DOI":"10.3389\/fcell.2021.751578","volume":"9","author":"X Song","year":"2021","unstructured":"Song X, Guo Y, Song P, et al. Non-coding RNAs in Regulating Tumor Angiogenesis. Front Cell Dev Biol. 2021;9:751578. https:\/\/doi.org\/10.3389\/fcell.2021.751578 IF: 5.3 Q1 B2.","journal-title":"Front Cell Dev Biol"},{"key":"3443_CR79","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.omtn.2022.03.012","volume":"28","author":"J Liu","year":"2022","unstructured":"Liu J, Zhang Q, Yang D, et al. The role of long non-coding RNAs in angiogenesis and anti-angiogenic therapy resistance in cancer. Mol Ther Nucleic Acids. 2022;28:397\u2013407. https:\/\/doi.org\/10.1016\/j.omtn.2022.03.012 IF: 6.5 Q1 B2 1 comment on PubPeer (by: Guillaume Cabanac).","journal-title":"Mol Ther Nucleic Acids"},{"key":"3443_CR80","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s10571-020-00995-z","volume":"42","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Liu Z-Z, Wu H, Kuang W-L. LncRNA H19 promotes cell proliferation, migration, and angiogenesis of glioma by regulating Wnt5a\/\u03b2-catenin pathway via targeting miR-342. Cell Mol Neurobiol. 2022;42:1065\u201377. https:\/\/doi.org\/10.1007\/s10571-020-00995-z IF: 7.4 Q1 B4.","journal-title":"Cell Mol Neurobiol"},{"key":"3443_CR81","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1161\/CIRCRESAHA.113.301824","volume":"113","author":"L Shi","year":"2013","unstructured":"Shi L, Fisslthaler B, Zippel N, et al. MicroRNA-223 antagonizes angiogenesis by targeting \u03b21 integrin and preventing growth factor signaling in endothelial cells. Circ Res. 2013;113:1320\u201330. https:\/\/doi.org\/10.1161\/CIRCRESAHA.113.301824 IF: 18.0 Q1 B1.","journal-title":"Circ Res"},{"key":"3443_CR82","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/onc.2010.465","volume":"30","author":"L Fang","year":"2011","unstructured":"Fang L, Deng Z, Shatseva T, et al. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-\u03b28. Oncogene. 2011;30:806\u201321. https:\/\/doi.org\/10.1038\/onc.2010.465 IF: 9.1 Q1 B1 1 comment on PubPeer (by: Andryala Dentata).","journal-title":"Oncogene"},{"key":"3443_CR83","doi-asserted-by":"publisher","unstructured":"Cosma L-S, Schlosser S, Tews HC, et al. Hereditary diffuse gastric cancer: molecular genetics, biological mechanisms and current therapeutic approaches. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms23147821 IF: 5.6 Q1 B3.","DOI":"10.3390\/ijms23147821"},{"key":"3443_CR84","doi-asserted-by":"publisher","first-page":"104316","DOI":"10.1016\/j.ejmg.2021.104316","volume":"64","author":"S Lobo","year":"2021","unstructured":"Lobo S, Benusiglio PR, Coulet F, et al. Cancer predisposition and germline CTNNA1 variants. Eur J Med Genet. 2021;64:104316. https:\/\/doi.org\/10.1016\/j.ejmg.2021.104316 IF: 2.2 Q3 B4.","journal-title":"Eur J Med Genet"},{"key":"3443_CR85","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.canlet.2017.02.035","volume":"395","author":"Y Li","year":"2017","unstructured":"Li Y, Wu Z, Yuan J, et al. Long non-coding RNA MALAT1 promotes gastric cancer tumorigenicity and metastasis by regulating vasculogenic mimicry and angiogenesis. Cancer Lett. 2017;395:31\u201344. https:\/\/doi.org\/10.1016\/j.canlet.2017.02.035 IF: 11.8 Q1 B1.","journal-title":"Cancer Lett"},{"key":"3443_CR86","doi-asserted-by":"publisher","first-page":"e3000734","DOI":"10.1371\/journal.pbio.3000734","volume":"18","author":"J Li","year":"2020","unstructured":"Li J, Zhao Y, Choi J, et al. Targeting miR-27a\/VE-cadherin interactions rescues cerebral cavernous malformations in mice. PLoS Biol. 2020;18:e3000734. https:\/\/doi.org\/10.1371\/journal.pbio.3000734 IF: 6.9 Q1 B1.","journal-title":"PLoS Biol"},{"key":"3443_CR87","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/1873-3468.12565","volume":"591","author":"W Gu","year":"2017","unstructured":"Gu W, Zhan H, Zhou X-Y, et al. MicroRNA-22 regulates inflammation and angiogenesis via targeting VE-cadherin. FEBS Lett. 2017;591:513\u201326. https:\/\/doi.org\/10.1002\/1873-3468.12565 IF: 3.1 Q2 B4.","journal-title":"FEBS Lett"},{"key":"3443_CR88","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/onc.2012.68","volume":"32","author":"F Muramatsu","year":"2013","unstructured":"Muramatsu F, Kidoya H, Naito H, et al. microRNA-125b inhibits tube formation of blood vessels through translational suppression of VE-cadherin. Oncogene. 2013;32:414\u201321. https:\/\/doi.org\/10.1038\/onc.2012.68 IF: 9.1 Q1 B1.","journal-title":"Oncogene"},{"key":"3443_CR89","doi-asserted-by":"publisher","first-page":"101686","DOI":"10.1016\/j.bbrep.2024.101686","volume":"38","author":"BC Casali","year":"2024","unstructured":"Casali BC, Baptista MP, Pachane BC, et al. Blockage of \u03b1v\u03b23 integrin in 3D culture of triple-negative breast cancer and endothelial cells inhibits migration and discourages endothelial-to-mesenchymal plasticity. Biochem Biophys Rep. 2024;38:101686. https:\/\/doi.org\/10.1016\/j.bbrep.2024.101686 IF: 3.3 Q3 B4.","journal-title":"Biochem Biophys Rep"},{"key":"3443_CR90","doi-asserted-by":"publisher","first-page":"5289","DOI":"10.18632\/oncotarget.6677","volume":"7","author":"H Al Thawadi","year":"2016","unstructured":"Al Thawadi H, Abu-Kaoud N, Al Farsi H, et al. VE-cadherin cleavage by ovarian cancer microparticles induces \u03b2-catenin phosphorylation in endothelial cells. Oncotarget. 2016;7:5289\u2013305. https:\/\/doi.org\/10.18632\/oncotarget.6677 IF: NA NA NA 3 comments on PubPeer (by: Hypsidia Robinsoni).","journal-title":"Oncotarget"},{"key":"3443_CR91","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.canlet.2015.05.009","volume":"364","author":"N Shao","year":"2015","unstructured":"Shao N, Lu Z, Zhang Y, et al. Interleukin-8 upregulates integrin \u03b23 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K\/Akt\/NF-\u03baB pathway. Cancer Lett. 2015;364:165\u201372. https:\/\/doi.org\/10.1016\/j.canlet.2015.05.009 IF: 11.8 Q1 B1.","journal-title":"Cancer Lett"},{"key":"3443_CR92","doi-asserted-by":"publisher","first-page":"863850","DOI":"10.3389\/fcell.2022.863850","volume":"10","author":"C Bergonzini","year":"2022","unstructured":"Bergonzini C, Kroese K, Zweemer AJM, Danen EHJ. Targeting integrins for cancer therapy - disappointments and opportunities. Front Cell Dev Biol. 2022;10:863850. https:\/\/doi.org\/10.3389\/fcell.2022.863850 IF: 5.3 Q1 B2.","journal-title":"Front Cell Dev Biol"},{"key":"3443_CR93","doi-asserted-by":"publisher","unstructured":"Ranga V, Dakal TC, Maurya PK, et al. Role of RGD-binding Integrins in ovarian cancer progression, metastasis and response to therapy. Integr Biol (Camb). 2025;17. https:\/\/doi.org\/10.1093\/intbio\/zyaf003 IF: 2.0 Q4 B4.","DOI":"10.1093\/intbio\/zyaf003"},{"key":"3443_CR94","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/1947601912450586","volume":"2","author":"DA Reardon","year":"2011","unstructured":"Reardon DA, Cheresh D. Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer. 2011;2:1159\u201365. https:\/\/doi.org\/10.1177\/1947601912450586 IF: NA NA NA.","journal-title":"Genes Cancer"},{"key":"3443_CR95","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/ijc.34344","volume":"152","author":"C Seliger","year":"2023","unstructured":"Seliger C, Oppong FB, Lefranc F, et al. Association of antidepressant drug use with outcome of patients with glioblastoma. Int J Cancer. 2023;152:1348\u201359. https:\/\/doi.org\/10.1002\/ijc.34344 IF: 4.9 Q2 B2.","journal-title":"Int J Cancer"},{"key":"3443_CR96","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/cncr.24821","volume":"116","author":"P Hersey","year":"2010","unstructured":"Hersey P, Sosman J, O\u2019Day S, et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer. 2010;116:1526\u201334. https:\/\/doi.org\/10.1002\/cncr.24821 IF: 5.6 Q1 B1.","journal-title":"Cancer"},{"key":"3443_CR97","doi-asserted-by":"publisher","first-page":"e6800","DOI":"10.1002\/cam4.6800","volume":"13","author":"H Javid","year":"2024","unstructured":"Javid H, Oryani MA, Rezagholinejad N, et al. RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions. Cancer Med. 2024;13:e6800. https:\/\/doi.org\/10.1002\/cam4.6800 IF: 3.5 Q2 B3.","journal-title":"Cancer Med"},{"key":"3443_CR98","doi-asserted-by":"publisher","unstructured":"de Pellegars-Malhortie A, Picque Lasorsa L, Mazard T, et al. Why Is Wnt\/\u03b2-Catenin Not Yet Targeted in Routine Cancer Care? Pharmaceuticals (Basel). 2024;17. https:\/\/doi.org\/10.3390\/ph17070949 IF: 5.7 Q1 B3.","DOI":"10.3390\/ph17070949"},{"key":"3443_CR99","doi-asserted-by":"publisher","first-page":"177137","DOI":"10.1016\/j.ejphar.2024.177137","volume":"986","author":"NA Menon","year":"2025","unstructured":"Menon NA, Kumar CD, Ramachandran P, et al. Small-molecule inhibitors of WNT signalling in cancer therapy and their links to autophagy and apoptosis. Eur J Pharmacol. 2025;986:177137. https:\/\/doi.org\/10.1016\/j.ejphar.2024.177137 IF: 5.7 Q1 B3.","journal-title":"Eur J Pharmacol"},{"key":"3443_CR100","doi-asserted-by":"publisher","first-page":"1114822","DOI":"10.3389\/fonc.2023.1114822","volume":"13","author":"D Doucet","year":"2023","unstructured":"Doucet D, Brubaker C, Turner D, Gregory CA. Factors affecting the role of canonical Wnt inhibitor Dickkopf-1 in cancer progression. Front Oncol. 2023;13:1114822. https:\/\/doi.org\/10.3389\/fonc.2023.1114822 IF: 3.4 Q2 B3.","journal-title":"Front Oncol"},{"key":"3443_CR101","first-page":"330","volume":"9","author":"O Lyros","year":"2019","unstructured":"Lyros O, Lamprecht A-K, Nie L, et al. Dickkopf-1 (DKK1) promotes tumor growth via Akt-phosphorylation and independently of Wnt-axis in Barrett\u2019s associated esophageal adenocarcinoma. Am J Cancer Res. 2019;9:330\u201346.","journal-title":"Am J Cancer Res"},{"key":"3443_CR102","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1038\/s41388-021-01860-z","volume":"40","author":"H Kimura","year":"2021","unstructured":"Kimura H, Sada R, Takada N, et al. The Dickkopf1 and FOXM1 positive feedback loop promotes tumor growth in pancreatic and esophageal cancers. Oncogene. 2021;40:4486\u2013502. https:\/\/doi.org\/10.1038\/s41388-021-01860-z IF: 9.1 Q1 B1.","journal-title":"Oncogene"},{"key":"3443_CR103","doi-asserted-by":"publisher","first-page":"8829649","DOI":"10.1155\/2022\/8829649","volume":"2022","author":"P Yu","year":"2022","unstructured":"Yu P, He W, Zhang Y, et al. SFRP4 Is a Potential Biomarker for the Prognosis and Immunotherapy for Gastric Cancer. J Oncol. 2022;2022:8829649. https:\/\/doi.org\/10.1155\/2022\/8829649 IF: NA NA NA.","journal-title":"J Oncol"},{"key":"3443_CR104","doi-asserted-by":"publisher","first-page":"274","DOI":"10.17305\/bb.2025.13047","volume":"26","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Wang L, Li Y, et al. Secreted frizzled-related protein 4 (sFRP4) in cancer - Dual roles in tumorigenesis and therapeutic potential: A review. Biomolecules Biomed. 2025;26:274\u201384. https:\/\/doi.org\/10.17305\/bb.2025.13047 IF: 2.8 Q3 B4.","journal-title":"Biomolecules Biomed"},{"key":"3443_CR105","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1158\/1541-7786.MCR-22-0508","volume":"20","author":"H Li","year":"2022","unstructured":"Li H, Zhao J, Sun J, et al. Correction: Demethylation of the SFRP4 Promoter Drives Gastric Cancer Progression via the Wnt Pathway. Mol Cancer Res. 2022;20:1467. https:\/\/doi.org\/10.1158\/1541-7786.MCR-22-0508 IF: 5.8 Q1 B2.","journal-title":"Mol Cancer Res"},{"key":"3443_CR106","doi-asserted-by":"publisher","unstructured":"Jhe Y-L, Lee S, Jung Y, Cheong J-H. PKA-Mediated Phosphorylation of SFRP4 Promotes Wnt\/\u03b2-Catenin Activation and Cancer Stemness in Gastric Cancer. Int J Mol Sci. 2025;26. https:\/\/doi.org\/10.3390\/ijms26125572 IF: 5.6 Q1 B3.","DOI":"10.3390\/ijms26125572"},{"key":"3443_CR107","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1158\/0008-5472.CAN-20-2041","volume":"81","author":"A Belur Nagaraj","year":"2021","unstructured":"Belur Nagaraj A, Knarr M, Sekhar S, et al. The miR-181a-SFRP4 axis regulates Wnt activation to drive stemness and platinum resistance in ovarian cancer. Cancer Res. 2021;81:2044\u201355. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-2041 IF: 22.6 Q1 B1.","journal-title":"Cancer Res"},{"key":"3443_CR108","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.1002\/cam4.4788","volume":"11","author":"J Wu","year":"2022","unstructured":"Wu J, Feng Z, Wang R, et al. Integration of bioinformatics analysis and experimental validation identifies plasma exosomal miR-103b\/877-5p\/29c-5p as diagnostic biomarkers for early lung adenocarcinoma. Cancer Med. 2022;11:4411\u201321. https:\/\/doi.org\/10.1002\/cam4.4788 IF: 3.5 Q2 B3.","journal-title":"Cancer Med"},{"key":"3443_CR109","doi-asserted-by":"publisher","first-page":"10964","DOI":"10.18632\/oncotarget.3696","volume":"6","author":"C Ge","year":"2015","unstructured":"Ge C, Wu S, Wang W, et al. miR-942 promotes cancer stem cell-like traits in esophageal squamous cell carcinoma through activation of Wnt\/\u03b2-catenin signalling pathway. Oncotarget. 2015;6:10964\u201377. https:\/\/doi.org\/10.18632\/oncotarget.3696 IF: NA NA NA.","journal-title":"Oncotarget"},{"key":"3443_CR110","doi-asserted-by":"publisher","first-page":"121384","DOI":"10.1016\/j.lfs.2023.121384","volume":"316","author":"SM Sundaram","year":"2023","unstructured":"Sundaram SM, Varier L, Fathima KZ, et al. Short peptide domains of the Wnt inhibitor sFRP4 target ovarian cancer stem cells by neutralizing the Wnt \u03b2-catenin pathway, disrupting the interaction between \u03b2-catenin and CD24 and suppressing autophagy. Life Sci. 2023;316:121384. https:\/\/doi.org\/10.1016\/j.lfs.2023.121384 IF: 6.4 Q1 B3.","journal-title":"Life Sci"},{"key":"3443_CR111","doi-asserted-by":"publisher","unstructured":"Bhuvanalakshmi G, Gamit N, Patil M, et al. Stemness, Pluripotentiality, and Wnt Antagonism: sFRP4, a Wnt antagonist Mediates Pluripotency and Stemness in Glioblastoma. Cancers (Basel). 2018;11. https:\/\/doi.org\/10.3390\/cancers11010025 IF: 4.8 Q2 B3.","DOI":"10.3390\/cancers11010025"},{"key":"3443_CR112","doi-asserted-by":"publisher","unstructured":"Yasmin IA, Dharmarajan A, Warrier S. iPSC-Derived Glioblastoma Cells Have Enhanced Stemness Wnt\/\u03b2-Catenin Activity Which Is Negatively Regulated by Wnt Antagonist sFRP4. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15143622 IF: 4.8 Q2 B3.","DOI":"10.3390\/cancers15143622"},{"key":"3443_CR113","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3727\/096504013X13786659070154","volume":"21","author":"S Warrier","year":"2013","unstructured":"Warrier S, Balu SK, Kumar AP, et al. Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), increases chemotherapeutic response of glioma stem-like cells. Oncol Res. 2013;21:93\u2013102. https:\/\/doi.org\/10.3727\/096504013X13786659070154 IF: 4.6 Q2 B4.","journal-title":"Oncol Res"},{"key":"3443_CR114","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fphar.2017.00124","volume":"8","author":"G Bhuvanalakshmi","year":"2017","unstructured":"Bhuvanalakshmi G, Basappa, Rangappa KS, et al. Breast Cancer Stem-Like Cells Are Inhibited by Diosgenin, a Steroidal Saponin, by the Attenuation of the Wnt \u03b2-Catenin Signaling via the Wnt Antagonist Secreted Frizzled Related Protein-4. Front Pharmacol. 2017;8:124. https:\/\/doi.org\/10.3389\/fphar.2017.00124 IF: 5.4 Q1 B3.","journal-title":"Front Pharmacol"},{"key":"3443_CR115","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/cgt.2014.42","volume":"21","author":"S Warrier","year":"2014","unstructured":"Warrier S, Bhuvanalakshmi G, Arfuso F, et al. Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition. Cancer Gene Ther. 2014;21:381\u20138. https:\/\/doi.org\/10.1038\/cgt.2014.42 IF: 6.4 Q1 B3.","journal-title":"Cancer Gene Ther"},{"key":"3443_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-023-01264-4","volume":"21","author":"S Li","year":"2023","unstructured":"Li S, Sampson C, Liu C, et al. Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities. Cell Communication Signal. 2023;21:1\u201319. https:\/\/doi.org\/10.1186\/s12964-023-01264-4 IF: 11.6 Q1 B2.","journal-title":"Cell Communication Signal"},{"key":"3443_CR117","doi-asserted-by":"publisher","first-page":"eaay3704","DOI":"10.1126\/sciadv.aay3704","volume":"6","author":"D Gay","year":"2020","unstructured":"Gay D, Ghinatti G, Guerrero-Juarez CF, et al. Phagocytosis of Wnt inhibitor SFRP4 by late wound macrophages drives chronic Wnt activity for fibrotic skin healing. Sci Adv. 2020;6:eaay3704. https:\/\/doi.org\/10.1126\/sciadv.aay3704 IF: 13.9 Q1 B1.","journal-title":"Sci Adv"},{"key":"3443_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3727\/096504012x13425470196010","volume":"20","author":"D Longman","year":"2012","unstructured":"Longman D, Arfuso F, Viola HM, et al. The role of the cysteine-rich domain and netrin-like domain of secreted frizzled-related protein 4 in angiogenesis inhibition in vitro. Oncol Res. 2012;20:1\u20136. https:\/\/doi.org\/10.3727\/096504012x13425470196010 IF: 4.6 Q2 B4.","journal-title":"Oncol Res"},{"key":"3443_CR119","doi-asserted-by":"publisher","unstructured":"Bogdanovi\u0107 B, Fagret D, Ghezzi C, Montemagno C. Integrin targeting and beyond: enhancing cancer treatment with dual-targeting RGD (Arginine-Glycine-Aspartate) strategies. Pharmaceuticals (Basel). 2024;17. https:\/\/doi.org\/10.3390\/ph17111556 IF: 5.7 Q1 B3.","DOI":"10.3390\/ph17111556"},{"key":"3443_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-026-02828-w","author":"P Agarwal","year":"2026","unstructured":"Agarwal P, Raman R, Agarwal P, et al. Integrins in cancer: insights into mechanisms and therapeutic potential. Cell Commun Signal. 2026. https:\/\/doi.org\/10.1186\/s12964-026-02828-w IF: 11.6 Q1 B2. 24","journal-title":"Cell Commun Signal"},{"key":"3443_CR121","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nm.1941","volume":"15","author":"AR Reynolds","year":"2009","unstructured":"Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med. 2009;15:392\u2013400. https:\/\/doi.org\/10.1038\/nm.1941 IF: 52.5 Q1 B1.","journal-title":"Nat Med"},{"key":"3443_CR122","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.tcb.2018.12.005","volume":"29","author":"A Becchetti","year":"2019","unstructured":"Becchetti A, Petroni G, Arcangeli A. Ion channel conformations regulate integrin-dependent signaling. Trends Cell Biol. 2019;29:298\u2013307. https:\/\/doi.org\/10.1016\/j.tcb.2018.12.005 IF: 25.3 Q1 B1.","journal-title":"Trends Cell Biol"},{"key":"3443_CR123","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.tcb.2024.02.011","volume":"34","author":"F Jaudon","year":"2024","unstructured":"Jaudon F, Cingolani LA. Unlocking mechanosensitivity: integrins in neural adaptation. Trends Cell Biol. 2024;34:1029\u201343. https:\/\/doi.org\/10.1016\/j.tcb.2024.02.011 IF: 25.3 Q1 B1.","journal-title":"Trends Cell Biol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03443-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03443-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03443-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:16:48Z","timestamp":1792469808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03443-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":123,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3443"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03443-y","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"340"}}